Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabhalta
Pharma
Novartis presses pause on Fabhalta lupus nephritis trial
Amid a steady advance of kidney-focused label expansions, Novartis’ Fabhalta is slowing its roll in a key potential autoimmune niche.
Fraiser Kansteiner
Oct 19, 2026 10:13am
FDA grants full approval to Novartis' Fabhalta in IgAN
Jul 17, 2026 11:33am
Novartis sues AZ's Alexion over 'misleading' Ultomiris marketing
Oct 22, 2025 1:19pm
Novartis advances IgAN efforts with another phase 3 win
Oct 16, 2025 9:30am
Novartis earns FDA ire for 'misleading' Fabhalta ad imagery
Sep 30, 2025 11:12am
Apellis snatches broad kidney disease expansion for Empaveli
Jul 28, 2025 8:00pm
